These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 35540911)
1. Novel spirocyclic tranylcypromine derivatives as lysine-specific demethylase 1 (LSD1) inhibitors. Shi Y; Wu YR; Su MB; Shen DH; Gunosewoyo H; Yang F; Li J; Tang J; Zhou YB; Yu LF RSC Adv; 2018 Jan; 8(3):1666-1676. PubMed ID: 35540911 [TBL] [Abstract][Full Text] [Related]
2. Tying up tranylcypromine: Novel selective histone lysine specific demethylase 1 (LSD1) inhibitors. Ji YY; Lin SD; Wang YJ; Su MB; Zhang W; Gunosewoyo H; Yang F; Li J; Tang J; Zhou YB; Yu LF Eur J Med Chem; 2017 Dec; 141():101-112. PubMed ID: 29031059 [TBL] [Abstract][Full Text] [Related]
3. New tranylcypromine derivatives containing sulfonamide motif as potent LSD1 inhibitors to target acute myeloid leukemia: Design, synthesis and biological evaluation. Liang L; Wang H; Du Y; Luo B; Meng N; Cen M; Huang P; Ganesan A; Wen S Bioorg Chem; 2020 Jun; 99():103808. PubMed ID: 32334189 [TBL] [Abstract][Full Text] [Related]
4. Structure-activity studies on N-Substituted tranylcypromine derivatives lead to selective inhibitors of lysine specific demethylase 1 (LSD1) and potent inducers of leukemic cell differentiation. Schulz-Fincke J; Hau M; Barth J; Robaa D; Willmann D; Kürner A; Haas J; Greve G; Haydn T; Fulda S; Lübbert M; Lüdeke S; Berg T; Sippl W; Schüle R; Jung M Eur J Med Chem; 2018 Jan; 144():52-67. PubMed ID: 29247860 [TBL] [Abstract][Full Text] [Related]
5. Biochemical, structural, and biological evaluation of tranylcypromine derivatives as inhibitors of histone demethylases LSD1 and LSD2. Binda C; Valente S; Romanenghi M; Pilotto S; Cirilli R; Karytinos A; Ciossani G; Botrugno OA; Forneris F; Tardugno M; Edmondson DE; Minucci S; Mattevi A; Mai A J Am Chem Soc; 2010 May; 132(19):6827-33. PubMed ID: 20415477 [TBL] [Abstract][Full Text] [Related]
6. Irreversible LSD1 Inhibitors: Application of Tranylcypromine and Its Derivatives in Cancer Treatment. Zheng YC; Yu B; Jiang GZ; Feng XJ; He PX; Chu XY; Zhao W; Liu HM Curr Top Med Chem; 2016; 16(19):2179-88. PubMed ID: 26881714 [TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of tranylcypromine derivatives as novel LSD1/HDACs dual inhibitors for cancer treatment. Duan YC; Ma YC; Qin WP; Ding LN; Zheng YC; Zhu YL; Zhai XY; Yang J; Ma CY; Guan YY Eur J Med Chem; 2017 Nov; 140():392-402. PubMed ID: 28987602 [TBL] [Abstract][Full Text] [Related]
8. trans-2-Phenylcyclopropylamine is a mechanism-based inactivator of the histone demethylase LSD1. Schmidt DM; McCafferty DG Biochemistry; 2007 Apr; 46(14):4408-16. PubMed ID: 17367163 [TBL] [Abstract][Full Text] [Related]
9. Pure Diastereomers of a Tranylcypromine-Based LSD1 Inhibitor: Enzyme Selectivity and In-Cell Studies. Valente S; Rodriguez V; Mercurio C; Vianello P; Saponara B; Cirilli R; Ciossani G; Labella D; Marrocco B; Ruoppolo G; Botrugno OA; Dessanti P; Minucci S; Mattevi A; Varasi M; Mai A ACS Med Chem Lett; 2015 Feb; 6(2):173-7. PubMed ID: 25699146 [TBL] [Abstract][Full Text] [Related]
10. Pure enantiomers of benzoylamino-tranylcypromine: LSD1 inhibition, gene modulation in human leukemia cells and effects on clonogenic potential of murine promyelocytic blasts. Valente S; Rodriguez V; Mercurio C; Vianello P; Saponara B; Cirilli R; Ciossani G; Labella D; Marrocco B; Monaldi D; Ruoppolo G; Tilset M; Botrugno OA; Dessanti P; Minucci S; Mattevi A; Varasi M; Mai A Eur J Med Chem; 2015 Apr; 94():163-74. PubMed ID: 25768700 [TBL] [Abstract][Full Text] [Related]
11. Discovery of new tranylcypromine derivatives as highly potent LSD1 inhibitors. Huang MJ; Guo JW; Fu YD; You YZ; Xu WY; Song TY; Li R; Chen ZT; Huang LH; Liu HM Bioorg Med Chem Lett; 2021 Jun; 41():127993. PubMed ID: 33775841 [TBL] [Abstract][Full Text] [Related]
13. Novel Tranylcypromine/Hydroxylcinnamic Acid Hybrids as Lysine-Specific Demethylase 1 Inhibitors with Potent Antitumor Activity. Han Y; Wu C; Lv H; Liu N; Deng H Chem Pharm Bull (Tokyo); 2015; 63(11):882-9. PubMed ID: 26521853 [TBL] [Abstract][Full Text] [Related]
14. An Update of Lysine Specific Demethylase 1 Inhibitor: A Patent Review (2016-2020). Zheng YC; Liu YJ; Gao Y; Wang B; Liu HM Recent Pat Anticancer Drug Discov; 2022; 17(1):9-25. PubMed ID: 34323202 [TBL] [Abstract][Full Text] [Related]
15. Crystal structure of histone demethylase LSD1 and tranylcypromine at 2.25 A. Mimasu S; Sengoku T; Fukuzawa S; Umehara T; Yokoyama S Biochem Biophys Res Commun; 2008 Feb; 366(1):15-22. PubMed ID: 18039463 [TBL] [Abstract][Full Text] [Related]
16. Design and Synthesis of Tranylcypromine-Derived LSD1 Inhibitors with Improved hERG and Microsomal Stability Profiles. Koda Y; Sato S; Yamamoto H; Niwa H; Watanabe H; Watanabe C; Sato T; Nakamura K; Tanaka A; Shirouzu M; Honma T; Fukami T; Koyama H; Umehara T ACS Med Chem Lett; 2022 May; 13(5):848-854. PubMed ID: 35586426 [TBL] [Abstract][Full Text] [Related]
17. QSAR Modeling, Molecular Docking and Molecular Dynamics Simulations Studies of Lysine-Specific Demethylase 1 (LSD1) Inhibitors as Anticancer Agents. Abdizadeh R; Heidarian E; Hadizadeh F; Abdizadeh T Anticancer Agents Med Chem; 2021; 21(8):987-1018. PubMed ID: 32698753 [TBL] [Abstract][Full Text] [Related]
18. Development of the triazole-fused pyrimidine derivatives as highly potent and reversible inhibitors of histone lysine specific demethylase 1 (LSD1/KDM1A). Li Z; Ding L; Li Z; Wang Z; Suo F; Shen D; Zhao T; Sun X; Wang J; Liu Y; Ma L; Zhao B; Geng P; Yu B; Zheng Y; Liu H Acta Pharm Sin B; 2019 Jul; 9(4):794-808. PubMed ID: 31384539 [TBL] [Abstract][Full Text] [Related]